Compare STAA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | MPLT |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1995 | N/A |
| Metric | STAA | MPLT |
|---|---|---|
| Price | $29.00 | $29.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $22.81 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 640.9K | 268.8K |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $288.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $12.24 |
| 52 Week High | $35.87 | $33.28 |
| Indicator | STAA | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 50.79 |
| Support Level | $28.03 | $26.07 |
| Resistance Level | $31.05 | $31.69 |
| Average True Range (ATR) | 1.00 | 2.49 |
| MACD | -0.28 | -0.11 |
| Stochastic Oscillator | 36.09 | 56.23 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.